Scott Buzby

SAN ANTONIO — Patient interviews showed weight loss via GLP-1 receptor agonists is a major emotional journey, many have anxiety surrounding cessation and weight regain due to lack of access, a speaker reported.

SAN ANTONIO — The disruptive SELECT trial not only bolstered the idea of medical obesity therapy as an avenue for heart disease prevention, its subanalyses continue to generate interesting new hypotheses, speakers reported.

SAN ANTONIO — Researchers identified several factors associated with likelihood of obesity drug prescription among youths, including female sex, higher

SAN ANTONIO — Tirzepatide demonstrated long-term weight-loss benefits and prevention of diabetes progression in patients with obesity and prediabetes, but

SAN ANTONIO — Petrelintide, a novel once-weekly amylin analog, was well-tolerated in a cohort of healthy people with overweight or obesity, while conferring up to 8.6% weight loss at 16 weeks, a speaker reported.

SAN ANTONIO — In patients with obesity, the novel triple receptor agonist retatrutide was associated with improvement in health-related quality of life vs. placebo, a speaker reported.

Key takeaways: Implementation science remains the largest challenges to widespread use of AI in medicine.

SAN ANTONIO — A swallowable hydrogel capsule that expands in the stomach demonstrated significant weight-loss, cardiovascular, glycemic and quality of life benefits for patients with overweight or obesity, a speaker reported.

Key takeaways: Solicitation of clinician input during AI tool development often happens late stage, if at all.

SAN ANTONIO — Once-daily oral semaglutide conferred more weight loss vs. placebo plus lifestyle intervention and was similar vs. larger oral GLP-1